Loading
A phase 2 trial of HS-20093 in osteosarcoma, run by Hansoh BioMedical R&D Company, now recruiting.
ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas is a phase 2 interventional study registered as NCT05830123 by Hansoh BioMedical R&D Company, with 170 participants planned, started 2023-06-08 and due to reach its primary completion in 2025-12-31. Interventions recorded: HS-20093. Conditions listed: Osteosarcoma, Sarcoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares HS-20093, Hansoh Pharmaceutical, Osteosarcoma.
Shares HS-20093, Hansoh Pharmaceutical.
Shares HS-20093, Hansoh Pharmaceutical.
Shares HS-20093, Hansoh Pharmaceutical.
Shares HS-20093, Hansoh Pharmaceutical.
Shares HS-20093, Hansoh Pharmaceutical.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/